Company intelligence / Profile preview
Samsung Bioepis
Songdo, Incheon, South Koreasamsungbioepis.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Samsung Bioepis has developed one of the most expansive and rapidly growing biosimilars portfolios in the industry. They have received European approval and FDA approval for multiple biosimilars including trastuzumab, ranibizumab, bevacizumab, and eculizumab biosimilars. Their product Opuviz was approved by the European Commission in November 2024.
- Therapeutic areas
- GastroenterologyOphthalmologyImmunologyEndocrinologyHematologyOncology
- Modalities
- BiosimilarsBiologic therapies
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Biogen (former joint venture partner)Organon
Beyond the preview
Go deeper on Samsung Bioepis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Samsung Bioepis.